Introduction Gestational trophoblastic neoplasia (GTN) are a rare group of tumors that arise from the placental villous

Methods We report the presenting features, treatment, and outcomes of patients diagnosed to have GTN over a nine-year period in a single institution. Patients diagnosed to have hydatidiform mole were excluded

Results Between 2013 and 2022, a total of 8 patients were diagnosed to have GTN. Median age was 37 (26–52) years. One patient was diagnosed to have metastatic disease 2 years after menopause. Six patients presented with vaginal bleeding, and one each with dyspnea and headache. Three patients had an antecedent history of hydatidiform mole, while 4 patients had antecedent full-term pregnancy. One patient presented with CNS metastasis, while one had co-incidental atypical meningioma. 05 patients presented with pulmonary metastasis. Splenic artery embolization was employed in one patient to arrest spontaneous retro-peritoneal bleed. Pre-treatment human chorionic gonadotropin (β-HCG) ranged between 4,300 to 1.29×10⁶ IU/L. According to the FIGO criteria, six patients had high risk disease. These patients received either EMA/CO (etoposide, methotrexate and actinomycin, oncovin cyclophosphamide) (4 patients), or BEP (2 patients). One patient required hysterectomy. Median time to response was 6.8 (04 to 12) weeks. Treatment was continued for 06 weeks after serological remission. All patients are in continuous complete remission

Conclusion/Implications The prevalence of GTN among Omani population is unknown and there is need to collect and report data on consecutive patients. Standard-of-care treatment ensures an excellent prognosis.